Advertisement
Loading...

Biogen Inc.

BIIB•NASDAQ
Healthcare
Drug Manufacturers - General
$192.95
$1.58(0.83%)
U.S. Market opens in 26h 56m

Biogen Inc. (BIIB) Stock Overview

Explore Biogen Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap28.5B
P/E Ratio20.68
EPS (TTM)$9.31
ROE0.08%
Fundamental Analysis

AI Price Forecasts

1 Month$165.81
3 Months$241.82
1 Year Target$115.21

BIIB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Biogen Inc. (BIIB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 53.66, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $115.21.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 20.68 and a market capitalization of 28.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
0.83%
5-Day Change
1.72%
1-Month Change
6.87%
3-Month Change
-1.82%
6-Month Change
15.16%
Year-to-Date (YTD) Change
9.64%
1-Year Change
55.98%
3-Year Change
-38.13%
5-Year Change
-31.19%
All-Time (Max) Change
6074.40%

Contact Information

https://www.biogen.com
617 679 2000
225 Binney Street, Cambridge, MA, 02142

Company Facts

7,605 Employees
IPO DateSep 17, 1991
CountryUS
Actively Trading

Frequently Asked Questions